Hepatitis C Virus Antigenic Convergence

Details

• Alternative Title:
  Sci Rep
• Personal Author:
  Campo, David S. ; Dimitrova, Zoya ; Yokosawa, Jonny ; Hoang, Duc ; Perez, Nestor O. ; Ramachandran, Sumathi ; Khudyakov, Yury
• Description:
  Vaccine development against hepatitis C virus (HCV) is hindered by poor understanding of factors defining cross-immunoreactivity among heterogeneous epitopes. Using synthetic peptides and mouse immunization as a model, we conducted a quantitative analysis of cross-immunoreactivity among variants of the HCV hypervariable region 1 (HVR1). Analysis of 26,883 immunological reactions among pairs of peptides showed that the distribution of cross-immunoreactivity among HVR1 variants was skewed, with antibodies against a few variants reacting with all tested peptides. The HVR1 cross-immunoreactivity was accurately modeled based on amino acid sequence alone. The tested peptides were mapped in the HVR1 sequence space, which was visualized as a network of 11,319 sequences. The HVR1 variants with a greater network centrality showed a broader cross-immunoreactivity. The entire sequence space is explored by each HCV genotype and subtype. These findings indicate that HVR1 antigenic diversity is extensively convergent and effectively limited, suggesting significant implications for vaccine development.
• Subjects:
  Animals Cross Reactions Epitopes Hepacivirus Hepatitis C Antigens Immunoenzyme Techniques Mice
• Source:
  Sci Rep. 2012; 2.
• Pubmed ID:
  22355779
• Pubmed Central ID:
  PMC3279735
• Document Type:
  Journal Article
• Volume:
  2
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:102cacfee60de123a53d07fbb76de388578d4569cd74ee71e1e6b4a2ae8a2d34
• Download URL:
  https://stacks.cdc.gov/view/cdc/8209/cdc_8209_DS1.pdf
• File Type:
  [PDF - 410.23 KB ]